Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.55 |
| ▸ | DRD3 | P35462 | 10/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7275892 | 0.83 | GRIN1 (0.44) | DRD2DRD3KCNH2GRIN1GRIN2B | |
| SCHEMBL5659873 | 0.79 | DRD2 (0.56) | DRD2DRD3MEN1NPC1RAB9A | |
| SCHEMBL14698020 | 0.77 | DRD2 (0.65) | DRD2DRD3MEN1NPC1RAB9A | |
| SCHEMBL5660117 | 0.75 | DRD2 (0.51) | DRD2DRD3MEN1NPC1RAB9A | |
| SCHEMBL6226262 | 0.74 | DRD2 (0.65) | DRD2DRD3MEN1NPC1RAB9A | |
| SCHEMBL5659037 | 0.74 | DRD2 (0.65) | DRD2DRD3MEN1NPC1RAB9A | |
| SCHEMBL8393737 | 0.74 | RAB9A (0.64) | DRD2DRD3MEN1NPC1RAB9A | |
| SCHEMBL8686095 | 0.72 | S1PR1 (0.60) | DRD2DRD3MEN1NPC1RAB9A | |
| SCHEMBL8572585 | 0.72 | DRD2 (0.55) | DRD2DRD3MEN1NPC1RAB9A | |
| SCHEMBL8416073 | 0.72 | DRD2 (0.55) | DRD2DRD3MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | DRD2 402/4885DRD3 395/4885MEN1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.